Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.


2024-11-08	-37	-119
2024-08-08	-43	-58
2024-05-14	-73	-82
2024-03-26	-144	-148
2023-11-09	-176	-216
2023-08-10	-227	-209
2023-05-08	-225	-180
2023-03-23	-165	-165
2022-11-01	-165	-180
2022-08-02	-165	-195
2022-05-09	-180	-225
2022-03-22	-405	-270
2021-11-11	-195	-255
2021-08-03	-225	-270
2021-05-04	-270	-255
2021-03-23	-255	-240
2020-11-10	-225	-270
2020-08-04	-315	-225
2020-05-05	-225	-150
2020-03-10	-195	-210
2019-11-05	-180	-195
2019-08-06	-195	-210
2019-05-07	-210	-255
2019-03-12	-255	-240
2018-11-06	-240	-285
2018-08-07	-450	-300
2018-05-10	-345	-180
2018-03-27	-180	-165
2017-11-14	-165	-195
2017-08-08	-165	-270
2017-05-11	-285	0
2017-03-28	-285	-24
2016-11-14	-360	-540
2016-08-09	-540	-480
2016-05-10	-465	-450
2016-03-29	-435	-360
2015-11-10	-315	-375
2015-08-04	-330	-465
2015-05-05	-375	-465
2015-03-03	-375	-465
2014-11-05	-480	0
2014-07-15	-48	-22
2014-04-10	-48	-77
2013-11-30	-1.08 K	0
2013-08-31	-444.94	0
2013-05-31	-532.03	0
2013-02-28	-570.53	0
2012-11-30	-691.78	0
2012-08-31	-541.84	0
2012-05-31	-726.8	0
2012-02-29	-874.9	0
2011-11-30	-1.2	0
2011-08-31	-1.18	0
2011-02-28	-1.85	0
2010-11-30	-1.96	0
2010-08-31	-1.99	0
2010-02-28	-2.31	0
2009-11-30	-2.39	0
2009-08-31	18.72	0
2009-05-31	-0.0010	0
2009-02-28	-4.14	0
2008-11-30	-3.97	0
2008-08-31	-4.93	0
2008-05-31	0.0010	0
2008-02-29	-9.83	0
2007-11-30	-7.12	0
2007-08-31	8.98	0
2007-05-31	-0.0010	0
2007-02-28	-4.52	0
2006-11-30	-7.02	0
2006-08-31	-7.26	0
2006-05-31	-12.65	0
2006-02-28	-11.18	0
2005-11-30	-13.63	0
2005-08-31	-15.12	0
2005-05-31	-1.99	0
2004-11-30	-15.72	0
2004-08-30	-14.95	0
2004-05-31	-17.5	0
2004-02-29	-19.23	0
2003-11-30	-14.55	0
2003-08-31	-18.58	0
2003-05-31	-11.32	0
2003-02-28	-9.58	0
2002-11-30	-9.49	0
2002-08-31	-9.78	0
2002-05-31	-8.3	0
2002-02-28	-7.09	0
2001-11-30	-8.88	0
2001-08-31	-7.48	0
2001-05-31	-9.49	0
2001-02-28	-6.85	0
2000-11-30	-9.55	0
2000-08-31	-6.64	0
2000-05-31	-9	0
2000-02-29	-11.16	0
1999-11-30	-3.67	0
1999-08-31	-7.23	0
1999-05-31	-11.13	0
1999-02-28	-7.16	0
1998-11-30	-10.55	0
1998-08-31	-13.67	0
1998-05-31	-12.05	0
1998-02-28	-15.52	0
1997-11-30	-15.18	0
1997-08-31	-11.66	0

Aptose Biosciences Inc.

APTO | NASDAQ Capital Market